Trade Mark Journal No.2026/004 23 January 2026

UK00004315098 23 December 2025 (5,42,44)

Mark 1

Image for mark UK00004315098_1of2 TRx

Mark 2

Image for mark UK00004315098_2of2
Class 5
Pharmaceutical and medical preparations; chemical preparations for medical and pharmaceutical purposes; pharmaceutical and medical preparations for use in relation to neurological diseases and disorders, neurodegenerative diseases and disorders, infectious diseases and malaria; chemical preparations for medical and pharmaceutical purposes for use in relation to neurological diseases and disorders, neurodegenerative diseases and disorders, infectious diseases and malaria.
Class 42
Medical, biological, biotechnological, genetic, laboratory and pharmaceutical research, design and development services; research, development and design of drugs and medicine; laboratory and medical laboratory research and development services; clinical research relating to neurodegenerative diseases; exploitation of scientific research and technology, preparation of reports; development of prognostic and diagnostic tools; testing and analysis services for the development of new drugs and medical treatments; consultancy and information services relating to all of the aforesaid.
Class 44
Medical clinic services; health resort services [medical]; services for the provision of medical facilities; medical services; medical advisory services; medical diagnostic testing, monitoring and reporting services; providing medical information, consultancy and advisory services; medical screening information services featuring reminder alerts regarding medical examinations that individuals should undergo for preventative care purposes; medical screening services in the fields of neurodegenerative and neurological diseases and disorders, malaria and infectious diseases; assessment surveys for health and medical purposes; medical and health care services relating to the diagnosis and treatment of dementia and cognitive disorders; medical analysis services for the diagnostic and prognostic monitoring of neurological diseases; consultancy and information services relating to all the aforesaid. .

TauRx Therapeutics Management Ltd.

Representative: Mewburn Ellis LLP